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"Quantifying and dissecting heritability allows us to counsel patients effectively and know where to 
focus our research efforts." 
 
Amyotrophic lateral sclerosis shows complex inheritance. A new study replicates previous 
estimates of the heritability due to common genetic variation and suggests possible disease-
associated loci. Despite such efforts, our understanding of the genetic architecture of amyotrophic 
lateral sclerosis remains limited. 
 
In any one person, amyotrophic lateral sclerosis (ALS) may be caused by environmental factors 
acting in concert with a single gene (monogenic), a few genes (oligogenic), or many (polygenic), with 
implications for genetic counselling and other information given to patients. One measure of the 
degree by which genetic variation influences the risk of a disease is heritability (BOX). An analysis by 
Keller and colleagues1 of three genome-wide association studies (GWAS) comprising 1,223 ALS cases 
and 1,591 controls reported a heritability estimate for ALS using a method called GREML, 
implemented in the genome-wide complex trait analysis software package GCTA.2  
 
An estimate of heritability is important to assess whether genetic variation influences the risk of ALS 
in people with no apparent family history. It does, as previously quantified from the risk of relatives,3 
heritability estimates from pedigree data4, 5 and from unrelated individuals using SNP data,6 
oligogenic and Mendelian mimics of sporadic ALS,7, 8 statistical models,9 consistency of diagnosis of 
familiality10 and the finding of Mendelian ALS genes in those with apparently sporadic ALS 
(http://alsod.iop.kcl.ac.uk). Quantifying and dissecting heritability allows us to counsel patients 
effectively and know where to focus our research efforts. In the context of GWAS, it quantifies the 
contribution of variation from common SNPs that can be identified using larger experimental sample 
sizes. 
 
Keller and colleagues report heritability as 21%, and contrast this with the result from an earlier 
study that reported an estimate of 12% from a larger set of 6,100 sporadic cases and 7,125 controls, 
that partly overlaps with the current study, and used identical methods. These estimates can be 
reconciled by noting that in addition to sampling variation, the two studies used different 
prevalences: 10 per 100,000 person-years for the study by Keller and colleagues, and 5 per 100,000 
for the earlier study. Indeed, the earlier study also estimated heritability of liability as 21% at a 
prevalence of 10 per 100,000.  
 
It is important to clarify that what Keller and colleagues report is not in fact the heritability of ALS, 
but rather the heritability of ALS that is captured by considering all common SNP variants 
simultaneously. ALS heritability estimates from twin studies are 76% (95% confidence interval 
60%,86%) when all cases are included and 61% (95% confidence interval 38%,78%) when familial 
cases are excluded,4 and in family studies they range from 40% to 60%:5 the twin and family studies 
estimate the total heritability of which part is due to common SNP variants. The remaining "hidden" 
heritability is likely to be found in rare variants, and other genetic variations such as copy number 
variants that are not captured by common SNPs. When heritability is estimated from pedigree data 
(e.g. in a twin study), it is blind with respect to the allelic spectrum of causal variants in the 
population. In contrast, heritability estimated from SNP data (as in this study) depends on the 
underlying genetic architecture. The contribution of low frequency variants, with a frequency of, say, 
less than 1 in 1000, will not be captured from GWAS data whereas it will in a pedigree study. 
 
The authors used samples from three groups: people with apparently sporadic ALS from an outbred 
Italian population, and samples from people with familial or sporadic ALS from a speciality clinic in 
Finland (a genetically homogeneous population), and from US based speciality clinics.1 One might 
expect the heritability estimate to differ between familial and sporadic samples and in this regard it 
is interesting that the heritability appeared the same in all three cohorts. This finding underlines 
previous work showing that the distinction between familial and sporadic cases is ambiguous, 
because clinicians are not uniform in their definitions,10 the probability of more than one person 
being affected depends on family size and penetrance,9 and there is an increased risk to relatives of 
those with sporadic ALS, probably because of oligogenic and polygenic effects.3, 8 The finding is also 
consistent with twin studies that show little change in heritability estimates with the inclusion or 
exclusion of familial samples.4,5 
 
A key and novel finding reported by Keller and colleagues is of genomic regions explaining a 
significant proportion of variation, and therefore possibly harbouring ALS genes. The authors used 
20Mb segments of the genome and applied GREML methods to each segment in each population, 
with regions of interest then broken down into 1Mb regions for further analysis.2 Results were then 
meta-analysed across the three populations. This is an interesting strategy, and an alternative to 
standard association testing using individuals SNPs, but requires care in interpretation, since 20 Mb 
regions can soak up variation from nearby regions due to linkage disequilibrium. 
 
This study replicates previous work on ALS heritability captured from common SNPs and confirms 
existing ideas about the role of genetic variation in apparently sporadic ALS.6 The estimates from the 
current and previous study are consistent and point to a role of common variants in ALS. The 
heritability explained from the few GWAS hits to date is less than 1%, implying that many more 
common loci are still to be found and that these can be detected when larger experimental sample 
sizes are used. Our understanding of the genetic architecture of ALS has been transformed in recent 
years by advances in genetic technologies, statistical and computing approaches to genetics, and our 
knowledge of the genome. Clinicians may find it difficult to keep up with such a rapidly changing 
field, but the message to our patients must remain based in evidence and consistent: there is a 
genetic component to ALS, but it varies in degree between people; the risk to relatives of someone 
with no family history remains small; and until there are effective therapies, genetic testing of 
affected individuals with no family history should only be undertaken after very careful 
consideration of the consequences. 
 
 
 
BOX  
Heritability is not the same as "genetic contribution". It is the proportion of phenotypic variance 
explained by genetic variance and can be estimated using different experimental designs.  
 
The heritability of having a head is zero, because there is no phenotypic variance (everyone has a 
head), even though having a head is clearly completely genetically determined.  
 
Heritability applies to populations, not individuals. Knowing the heritability of ALS tells us nothing 
about the genetic contribution to disease in an individual, or in a population of different ethnicity.   
 
For a quantitative trait, such as height, the phenotypic variance can be estimated from a population 
sample. For a discrete trait, such as ALS, geneticists assume an underlying liability to disease that is 
normally distributed and includes genetic and environmental components; only individuals carrying 
enough liability develop disease. Variation in observed risk reflects population prevalence, and is 
related to heritability on the risk scale.11 
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